Olive Leaf Extract (standardised oleuropein)

Supplements · §532

If your blood pressure is creeping into the 130s and you're hoping not to be on a pill, this is one of the few supplements with real trial evidence behind it. A standardised olive leaf extract — concentrated for the molecule called oleuropein, the part of the leaf that does the work — drops systolic blood pressure by roughly five points in people whose pressure is already elevated, with secondary nudges down in blood sugar and triglycerides. It is not olive oil in a capsule; it's a different preparation with its own trials. The effect is modest, the cost is around thirty to eighty dollars a year, and the honest pitch is narrow: borderline hypertension and borderline blood sugar, not a cure for either.

Do · Daily Evidence Emerging Chapter Supplements

A real, replicated effect on the numbers that matter for cardiovascular risk — blood pressure, blood sugar, triglycerides — earned over a couple of months of one capsule a day. The size of the win is small. If your blood pressure already reads 120/75 and your fasting sugar is normal, expect nothing. If it reads 138/85 and your fasting sugar drifts in the prediabetic range, this is among the better-evidenced cheap levers on the supplement shelf — though lifestyle and, when warranted, medication still hit harder.

Olive leaves are bitter for the same reason that an unripe olive is inedible — they're packed with a compound called oleuropein, the molecule the supplement is concentrated for. In the body, oleuropein and its breakdown product hydroxytyrosol do three things at once. They relax the smooth muscle in artery walls, the way a calcium-channel blocker does, which is what brings blood pressure down. They quiet inflammation in the lining of the blood vessels — the layer where artery damage starts — by blocking the molecular signals that recruit white blood cells onto the wall. And in the gut they slow the breakdown of starch into sugar, blunting the post-meal blood-sugar spike. Three different problems, one molecule, one mechanism family. That overlap is why the trial results read the same way across blood-pressure, blood-sugar, and lipid endpoints — they all sit downstream of vascular inflammation and metabolic stress.

What the trials actually show

The strongest single result is the head-to-head against a real blood-pressure drug. Susalit 2011 took 232 adults with mild hypertension and gave half of them olive leaf extract and half a low dose of captopril, an ACE inhibitor that family doctors prescribe every day. Eight weeks later, both groups had dropped by roughly the same amount — and the olive leaf group wasn't far behind the drug.

The placebo-controlled trials are smaller and the effect they find is smaller too. A crossover trial in 60 men with creeping blood pressure used 24-hour ambulatory monitoring — the gold standard, because clinic readings can be artificially high — and found a systolic drop of about three points on extract versus placebo (Lockyer et al. 2017). The 2025 multicentre trial, the largest to date, randomised 621 hypertensive adults and reported a 24-hour systolic drop of 6.4 mmHg from baseline on the extract versus 1.5 mmHg on placebo (Lamti et al. 2025). The two recent pooled analyses agree: a four-to-five-point systolic reduction in people whose pressure was already elevated, smaller and not always significant in mixed populations (Razmpoosh 2022, Ismail 2021).

The blood-sugar story is similar in shape: a real signal in the right person. In a 14-week trial of 79 adults with type-2 diabetes, the extract group's HbA_1c — the three-month average of blood sugar — fell significantly, and fasting insulin fell with it (Wainstein et al. 2012). In overweight middle-aged men without diabetes, twelve weeks of supplementation improved insulin sensitivity by about 15% and pancreatic beta-cell function by about 28% (de Bock et al. 2013). In healthy normoglycaemic adults the pooled effect on fasting glucose is not significant — the extract works on a metabolism that has already started to fail, not on one that's running fine.

Triglycerides and LDL come down by a clinically modest amount in the same population — call it half the size of what a low-dose statin does (Lockyer 2017, Razmpoosh 2022). The immune-system claims that fill the marketing copy rest on one in-hospital COVID-19 trial showing faster fever resolution and shorter stays (Ahmadpour et al. 2023) plus a stack of in-vitro antiviral work on influenza. There is no good outpatient cold-prevention trial; the "fewer colds" claim is community lore.

This is where the case stays honest. The numbers olive leaf extract moves — a few points off the top of the blood-pressure reading, a small downward drift in fasting sugar and triglycerides — feel like nothing in the body. You do not wake up and notice. What changes, slowly, is the line on the chart at your annual physical: the reading that has been rising for five years stops rising, or starts coming down. That is the whole experience. Over a decade, a sustained five-point drop in systolic pressure translates to roughly an 8–10% lower stroke risk and a 5–7% lower heart-attack risk at the population level — meaningful, but not anyone's life-changing moment.

The cost of ignoring this is the same shape: not dramatic, just compounding. The version of you whose blood pressure quietly drifts from 132 to 142 over five years is the version who, around year ten, has a conversation with a doctor about starting medication. There is nothing wrong with that conversation, and medication is more powerful than any supplement. The point isn't that this extract prevents that future; it's that for a specific reader — pressure in the 130s, sugar drifting, not yet on anything — it's a cheap lever that may move the curve a few years out, while the harder lifestyle work catches up.

How to take it

The clinically tested regimens land in a narrow band. Pick a product standardised to oleuropein content — the number that actually matters is on the supplement-facts panel as "standardised to X% oleuropein" or "X mg oleuropein". A bottle that says only "olive leaf 500 mg" with no percentage is the supplement-aisle equivalent of a wine bottle that doesn't list the alcohol — you have no idea what's in it.

The most-replicated effective dose in the trials is 500 mg of standardised extract twice a day — the regimen Susalit used against captopril. Perrinjaquet-Moccetti 2008 showed a clear dose-response: 500 mg/day was indistinguishable from the lifestyle-only control, while 1000 mg/day dropped systolic pressure by about eleven points. The retail products selling at lower doses or unspecified standardisation are likely subtherapeutic.

If you're pregnant or breastfeeding, skip it — there's no safety data either way, and the field default is to avoid herbal extracts whose effects in pregnancy haven't been studied. Allergy to olive-tree pollen is not the same as a reaction to the extract; the pill doesn't carry pollen protein. The trials in 600+ adults at clinical doses have not turned up serious side effects (Lamti 2025, MSK monograph).

Two confusions to clear up. First, this is not olive oil in a capsule. Olive oil carries a different and much smaller mix of plant compounds, mostly hydroxytyrosol and oleocanthal, in a fat matrix; you eat it with food. Olive leaf extract delivers a concentrated dose of oleuropein in a pill, on its own trials. The Mediterranean-diet evidence that puts olive oil into the conversation about heart disease — the large PREDIMED trial, for instance (Estruch et al. 2018) — does not carry over to the leaf extract, and the leaf-extract blood-pressure trials don't transfer to drizzling more oil on your salad. They are two different things that share a tree.

Second, the "immune booster" framing on the bottle is doing more work than the evidence allows. There is solid laboratory work showing oleuropein interferes with the influenza virus and other respiratory viruses in a dish, and one randomised trial in hospitalised COVID-19 patients showed faster recovery on the extract (Salamanca 2021, Ahmadpour 2023). There is not a good outpatient cold-prevention trial. People who take this hoping to catch fewer colds in winter are running ahead of what's been demonstrated; the cardiovascular and metabolic case is the case the evidence supports.

If the goal is to bring blood pressure down, two interventions hit harder than this one. Lifestyle — meaning sodium reduction, weight loss when there's weight to lose, regular aerobic exercise, and a DASH-pattern or Mediterranean-pattern diet — typically drops systolic pressure by eight to fourteen points when actually done, and it's free. A first-line medication (a low-dose ACE inhibitor, ARB, or thiazide) is more potent at proper titration, almost always covered by insurance, and is the right tool once readings cross into stage-2 territory or once organ-damage markers show up. Olive leaf extract sits between those two — a small additional lever you can stack on top of lifestyle while you wait for it to work, or use on its own if your readings are borderline and a clinician has signed off on watchful waiting.

For blood sugar, the comparable comment: metformin is dominant for type-2 diabetes, lifestyle (weight loss and exercise) is dominant for prediabetes, and the extract is at best an adjunct.

Three ways this goes nowhere. The first is the wrong product: a bottle labelled "olive leaf 500 mg" with no oleuropein percentage tells you nothing about dose. The percentage standardisation is the actual ingredient list. The second is the wrong reader: if your starting blood pressure is 118/76 and your fasting sugar is 88, the effect is zero by design — there isn't a number for the extract to bring down. That isn't the extract failing; that's the extract working only on the population the trials studied. The third is using it as a substitute when you needed medication: persistently reading 150/95, treating it with a supplement for six months, and skipping the doctor's visit is a bad trade. The trial-grade reductions are useful at the pre-hypertensive edge; they are not enough to manage moderate or severe hypertension on their own.

Available over the counter in most pharmacies and most supplement aisles, no prescription needed. A bottle of 60 capsules standardised to 20% oleuropein retails for roughly fifteen to twenty-five dollars and lasts a month or two at clinical dosing — annual cost lands in the thirty-to-eighty-dollar range, lower than almost any prescribed alternative. Shelf-stable, no refrigeration. The only practical friction is reading the label carefully enough to confirm the oleuropein standardisation; once that's done, the daily-use part is one swallow with breakfast.

The other practicality: pair it with a home blood-pressure cuff. Without before-and-after numbers you cannot tell whether you're in the responder group, and the responder group is the entire point. A cuff from a pharmacy costs about forty dollars and is the most useful piece of equipment a person with creeping blood pressure can own.

Honest about the timeline: the felt experience over the first month is nothing. No energy lift, no calmer mood, no sharper afternoons — this isn't that kind of supplement. What you're buying is a slow shift in the numbers. By the four-to-six-week mark, a home blood-pressure cuff used a few times a week should start to show a downward drift in the morning readings. By twelve weeks, the size of that drift in the trials lands around five points for people who started above 130 systolic (Lockyer 2017, Lamti 2025). The next routine blood draw, if you've been dysglycaemic, may show fasting glucose and triglycerides ticking down with it.

Over the longer run the payoff is the one you don't experience as a moment: the conversation about starting a blood-pressure medication, pushed a few years further out; a cardiovascular-risk number at your annual physical that doesn't keep creeping up. The decade-scale projection out of the BP-and-CV-risk literature — fewer strokes, fewer heart attacks — is real but population-statistical: it does not show up as anything you feel on a Tuesday morning. That's a fair trade for one capsule a day and the cost of a coffee a month, but it has to be the trade the reader wants.

Adjacent topics worth knowing about: extra-virgin olive oil and Mediterranean-pattern eating — a different substance with a much larger cardiovascular evidence base; home blood-pressure monitoring — without it, you can't tell whether this is doing anything; and the broader question of when borderline hypertension warrants medication, which is a conversation with a clinician rather than a supplement decision.

Substance and claimed effects

Olive leaf extract (OLE) is a concentrated preparation of the leaves of Olea europaea, standardised for its principal phenolic compound, oleuropein. The extract is sold as a daily supplement (capsules, tablets, or liquid), distinct from culinary olive oil — which carries a different and smaller phenolic profile dominated by hydroxytyrosol and oleocanthal — and from table olives. Commercial products are typically standardised to 15–40% oleuropein; the clinically tested doses fall in the range of 100–136 mg oleuropein per day, delivered as roughly 500–1000 mg of extract MSK monograph 2024. The trial-validated proprietary preparation EFLA943 (the basis of Perrinjaquet-Moccetti 2008 and Susalit 2011) is the closest thing to a standardised reference dose in the literature.

Claimed effects span four clusters, each with its own evidence base: (1) modest reductions in blood pressure in pre-hypertensive and stage-1 hypertensive adults; (2) improved insulin sensitivity and glycaemic control, particularly in overweight or type-2 diabetic adults; (3) modest improvements in the lipid profile (triglycerides, LDL); (4) antiviral / immunomodulatory activity, mostly preclinical, with one COVID-19 inpatient trial. The entry's holistic scope is the supplement and these four consequences taken together (per entry.md §1a). A fifth thread — symptomatic relief in postmenopausal women — has one positive trial Filip 2024 and is flagged but not foregrounded.

Evidence by addressing question

Mechanism

Oleuropein and its hydrolysis product hydroxytyrosol are the load-bearing molecules. Three converging mechanisms have been mapped in vitro and in animals, each consistent with the human-trial endpoints. Vasodilation: oleuropein acts as a calcium-channel-modulating vasodilator and reduces angiotensin-converting-enzyme activity in cell preparations, producing relaxation of vascular smooth muscle similar in net effect (though not in molecular target) to ACE inhibitors such as captopril Susalit 2011. Antioxidant / anti-inflammatory action on the endothelium: oleuropein scavenges superoxide and inhibits LDL oxidation; both oleuropein and hydroxytyrosol downregulate VCAM-1 / ICAM-1 expression on endothelial cells via NF-κB suppression, plausibly explaining the modest LDL and CRP reductions in Lockyer 2017 and Lamti 2025. Glucose handling: in rodent intestine, OLE acutely reduces starch digestion and absorption (an α-amylase / α-glucosidase inhibitor effect), and chronic dosing improves whole-body insulin sensitivity by mechanisms consistent with reduced oxidative stress on pancreatic β-cells Wainstein 2012, de Bock 2013.

Evidence

Blood pressure — the strongest signal. Susalit 2011 randomised 232 adults with stage-1 hypertension to 500 mg OLE (EFLA943) twice daily or captopril 12.5–25 mg twice daily for 8 weeks; mean systolic reduction was −11.5 mmHg on OLE vs −13.7 mmHg on captopril, with the two arms statistically non-inferior. Perrinjaquet-Moccetti 2008, the EFLA943 twin study, found dose-dependent BP reduction (≤ 13 mmHg systolic at 1000 mg/day, no change at 500 mg vs lifestyle control). Lockyer 2017, a crossover trial in 60 pre-hypertensive men using 136 mg/day oleuropein, reported 24-hour ambulatory systolic reductions of 3.3 mmHg and diastolic of 2.4 mmHg. The 2025 multicentre Lamti 2025 trial randomised 621 hypertensive adults to OLE or placebo for 12 weeks: 24-hour systolic dropped 6.4 mmHg from baseline in the OLE arm vs 1.5 mmHg on placebo, with secondary improvements in lipid profile, blood glucose, CRP, and body weight. The two pooled meta-analyses converge: Razmpoosh 2022 (12 RCTs, 819 participants) found −3.86 mmHg overall systolic and −4.81 mmHg / −2.45 mmHg in the hypertensive subgroup; Ismail 2021 (5 RCTs, 325 participants) reported −5.78 mmHg systolic at 500 mg/day.

Glycaemic control. Wainstein 2012 randomised 79 adults with type-2 diabetes to 500 mg/day OLE or placebo for 14 weeks; HbA_1c and fasting insulin dropped significantly in the OLE arm. de Bock 2013, a 12-week crossover in 46 overweight middle-aged men, found a 15% improvement in insulin sensitivity by the Matsuda index and a 28% improvement in pancreatic β-cell responsiveness. The pooled glucose signal in Razmpoosh 2022 across mixed populations was not significant — the glycaemic effect concentrates in dysglycaemic subgroups, not in healthy normoglycaemic adults.

Lipids. Triglyceride and LDL reductions are consistently present but small: Razmpoosh 2022 pooled −9.5 mg/dL triglycerides overall and −4.6 mg/dL LDL in the hypertensive subgroup. Lockyer 2017 reported total cholesterol −0.32 mmol/L and LDL −0.19 mmol/L. These are clinically modest — about half the magnitude of a low-dose statin — and concentrated in the hypertensive subgroup, suggesting they ride on the same vascular-inflammation pathway as the BP effect.

Immunity / antiviral. Preclinical evidence is solid: Salamanca 2021 demonstrated influenza-A neuraminidase inhibition and dose-dependent viral-replication suppression by an elenolic-acid-rich OLE in vitro and in mice. Human evidence is thin: Ahmadpour 2023, a triple-blinded RCT in 141 hospitalised COVID-19 patients, found significantly faster normalisation of body temperature, respiratory rate, CRP, ESR, and oxygen saturation in both OLE arms (250 mg and 500 mg bid) versus placebo, and shorter hospital stay. No high-quality outpatient cold/flu trial exists; community claims of "fewer colds" outrun the published evidence.

Postmenopausal symptoms. Filip 2024, a 12-week RCT in 60 women receiving 250 mg/day, found improvement in the MENQoL composite score and a small bone-mineral-density gain in the right arm. Hypothesis-generating; not a primary indication for the entry.

Protocol

The clinically tested regimens cluster around 500 mg standardised extract once or twice daily (yielding 100–200 mg oleuropein), taken with food. Susalit 2011 used 500 mg twice daily; Lockyer 2017 used a liquid form delivering 136 mg oleuropein once daily; Perrinjaquet-Moccetti 2008 demonstrated a dose-response between 500 and 1000 mg/day. Effect onset on BP appears within 4–6 weeks; full effect by 8–12 weeks. There is no loading protocol. The label key to check is standardised oleuropein content: the same milligram extract dose can deliver anywhere from 5 to 200 mg oleuropein depending on the standardisation, and unbranded or non-standardised olive-leaf powders likely do nothing.

Contraindications

Safety signal is benign in the trials: no adverse events at clinically meaningful rates across 600+ participants in the recent Lamti 2025 trial, and the captopril-comparison Susalit 2011 showed OLE was tolerated at least as well as the active comparator. Documented or theoretical concerns: (1) additive hypotension with prescribed antihypertensives, particularly ACE inhibitors and calcium-channel blockers — the mechanistic overlap is real MSK monograph; (2) additive hypoglycaemia with insulin and sulfonylureas in type-2 diabetes; (3) theoretical antiplatelet effect from oleuropein observed in vitro, warranting caution with warfarin and DOACs (no clinical bleeding signal yet); (4) pregnancy and breastfeeding — no safety data either way; standard "avoid" call. Olive-tree pollen is an allergen, but the extract itself does not carry pollen protein and ingested OLE has not been linked to allergic reactions MSK monograph.

Misconceptions

The most common reader confusion: olive leaf extract is not the same as olive oil. The polyphenol mix and concentration differ — extra-virgin olive oil delivers small daily doses of hydroxytyrosol and oleocanthal in a fat matrix and rides on the Mediterranean-diet evidence base (Estruch et al. 2018 / PREDIMED); olive leaf extract delivers concentrated oleuropein in pill form and rides on its own trials. The dietary case for olive oil does not transfer evidentially to OLE, and the BP / glucose evidence for OLE does not transfer to drizzling extra olive oil on a salad. Second misconception: the "immune-booster" framing in the supplement aisle outpaces the human data — there is one COVID-19 inpatient RCT and a lot of in-vitro work; there is no good outpatient cold-prevention trial.

Audience

Strongest signal: adults with elevated systolic blood pressure (130–159 mmHg) not yet on medication, and adults with type-2 diabetes or insulin resistance. For normotensive, normoglycaemic adults the effect size is small enough to be uninteresting — this is a targeted tool, not a universal supplement. Pre-menopausal women have only one direct trial; the postmenopausal MENQoL signal in Filip 2024 is a flag for that subgroup but not foregrounded.

Alternatives

For BP: lifestyle (DASH diet, sodium reduction, weight loss, exercise) outperforms OLE in effect size and has guideline backing; OLE is a supplement-shelf alternative, not a lifestyle substitute. Pharmacological alternatives (low-dose ACEi, ARB, thiazide) are more potent at proper titration, are guideline-first-line for confirmed hypertension, and are usually free under insurance. For glycaemic control: metformin remains the dominant tool; OLE is adjunctive at best.

Failure modes

Three common ones surface in the trials and the community signal: (1) non-standardised products — a generic "olive leaf 500 mg" with unspecified oleuropein content likely delivers a fraction of the clinical dose; (2) baseline-mismatch — a normotensive person taking OLE and seeing "nothing happen" is the predicted result, not failure; (3) self-treating moderate or severe hypertension — the absolute reductions of −5 mmHg systolic are useful at the pre-hypertensive margin but are not a substitute for medication when the reading is in stage-2 territory.

Practicalities

Cost: bottles of 60 capsules standardised to 20% oleuropein retail for roughly $15–25, translating to ~$30–80/year at clinical dosing. Effort: one or two capsules daily with food; no special timing, no titration. Storage: shelf-stable. Available without prescription in most jurisdictions. The key shelf-check is the standardisation percentage on the label; products that list "olive leaf 500 mg" without an oleuropein percentage are not equivalent to the trial preparations.

Stakes

The catalogue's loss-aversion case here is narrow: this is a small lever, not a watershed intervention. For an adult with systolic BP in the 130–145 mmHg band, the absolute risk reduction from a −5 mmHg sustained reduction translates to roughly an 8–10% relative reduction in stroke risk and 5–7% reduction in coronary events over a decade — meaningful at the population level but not transformative for any individual. The "stakes of ignoring" framing fits poorly; the honest framing is opportunity-cost on a cheap, low-effort lever for the specific population.

Payoff

For the right reader (pre-hypertensive, dysglycaemic, or both), the payoff is a 4–6 week trial that resolves into a clearer signal at the next routine BP / HbA_1c check, and over months a modest improvement in the cardiovascular-risk number-set. The felt experience is minimal — OLE is not a stimulant, mood-lifter, or sleep aid; readers chasing a sensation should expect nothing.

Out-of-scope

Adjacent topics worth flagging: extra-virgin olive oil and Mediterranean-pattern eating (different substance, much stronger CV evidence base via PREDIMED); home BP measurement (how the reader knows whether this is working); broader hypertension management (lifestyle, medication, when to consult a clinician).

The credibility range

Optimist case. The substance has a coherent mechanism (vasodilation + endothelial antioxidant action + α-glucosidase inhibition) traced through cell, animal, and human trials. Multiple independent RCTs, including a head-to-head against captopril, converge on a real BP effect of −5 to −11 mmHg systolic in hypertensives, with consistent glycaemic and lipid signals layered on top. The 2025 multicentre RCT (n=621) confirms the signal at population scale with placebo control. Safety is excellent across hundreds of participant-years. For pre-hypertensive and dysglycaemic adults, this is among the better-evidenced low-cost interventions in the supplement aisle — and the trials are unusually clean for a herbal product.

Skeptic case. The active-comparator trial (Susalit 2011) is the largest in absolute effect size but had no placebo arm; the placebo-controlled trials show smaller effects (−3 to −6 mmHg) with substantial placebo-arm BP reduction. Meta-analyses note moderate heterogeneity and rate evidence quality "moderate" for BP and lipids, "low" for glucose and inflammatory markers Razmpoosh 2022, Ismail 2021. Several trials are funded by proprietary-extract manufacturers, with publication-bias risk. The glycaemic signal in healthy adults disappears in pooled analysis. Antiviral / immune claims rest almost entirely on in-vitro and one inpatient COVID trial — no good outpatient evidence supports the "cold-prevention" marketing. The absolute effect on BP is smaller than first-line drug therapy and arguably smaller than diet-and-exercise interventions, so the opportunity-cost case (compared to lifestyle) is real.

Author's call. Real but modest. The blood-pressure effect in hypertensives is the strongest claim and is well-replicated; the glycaemic and lipid effects are real in dysglycaemic populations. Score evidence at 3 (multiple small/medium RCTs plus one good 2025 RCT plus two convergent meta-analyses, but no guideline endorsement and no large mortality trial). Score controversy at 2 (no foundational disagreement; minor pushback on placebo magnitudes and on extrapolating from in-vitro antiviral data). The honest reader-facing pitch is: a gentle adjunct lever for the specific reader with elevated BP or borderline blood sugar — not a universal supplement, not a substitute for medication when medication is warranted.

Stakeholder and incentive map

Commercial. EFLA943 and a handful of proprietary standardised extracts are sold by Frutarom / IFF and several Mediterranean supplement firms; many of the cleaner trials were industry-sponsored, which is normal for nutraceuticals but worth flagging. Generic OLE on Amazon is a much wider market with no quality oversight.
Practitioner. Naturopaths and functional-medicine clinicians have used OLE for "borderline hypertension" since at least the 1990s; conventional cardiology does not endorse it.
Community. Loud community signal for "immune support" and antiviral use, particularly during the COVID-19 period — outruns the human evidence.
Counter-incentive. The pharmaceutical case for under-treating mild hypertension with a supplement is the strongest skeptic position: someone who reaches for OLE instead of seeing a clinician about persistent stage-2 readings is harmed by the opportunity cost, not by the supplement.

Population variability

Hypertensives respond; normotensives don't. The pooled effect concentrates in the elevated-BP subgroup; Razmpoosh 2022.
Dysglycaemic / type-2 diabetic adults respond on HbA_1c; healthy normoglycaemics show no change.
Overweight men. The strongest mechanistic trial (de Bock 2013) was in middle-aged overweight men; the postmenopausal trial (Filip 2024) is small. Effect generalisation across sex is plausible but not heavily replicated.
Dose-response is real. Perrinjaquet-Moccetti 2008 showed 500 mg producing little effect while 1000 mg produced ~13 mmHg systolic reduction — the lower retail doses on the market may be subtherapeutic.

Knowledge gaps

No long-term (≥ 2-year) trials; cardiovascular event endpoints are inferred from BP / lipid surrogates, not measured.
No good outpatient cold/flu / upper-respiratory-infection prevention trial.
No head-to-head comparison against modern first-line antihypertensives (ARBs, low-dose chlorthalidone) at proper doses.
Standardisation in the retail market is inconsistent; bioavailability of oleuropein varies across preparations and is rarely reported.
Effect of OLE on top of a Mediterranean-pattern diet (incremental vs redundant) is unstudied.

Scope vs brief. Brief named blood pressure, blood sugar, immunity, and cardiovascular risk. Article covers BP and blood sugar/lipid endpoints in depth (the strongest evidence), and addresses the immunity claim honestly in misconceptions — the human evidence is one hospitalised-COVID RCT plus in-vitro work, which is not enough to put it in the front-page case. Cardiovascular risk is folded into the BP/lipid story (the only mechanism by which the substance touches CV risk).

Rating difficulties.

evidence: 3 was the hardest call. The Susalit 2011 active-comparator vs captopril, the 2025 multicentre 621-participant trial (Lamti), and two convergent meta-analyses make a strong case for 3, but the absence of a long-term hard-endpoint trial and the inconsistency in non-hypertensive populations kept it from 4. If a guideline body (AHA, ESC) adopts it in the next few years, push to 4.
longevity: 2 is inferred from BP/HbA_1c surrogate effects, not measured directly. Could be argued for 1; landed at 2 because the BP effect in hypertensives is the load-bearing argument and the surrogate-to-hard-endpoint translation is well-established for BP.
applicability: 3 — elevated BP is high-prevalence, but the entry is honest that the responder population is the hypertensive / dysglycaemic subgroup. Landed in the "large minority or one whole sex/age band" bucket.
mood: 0 — first considered 1 on the strength of Filip 2024's postmenopausal MENQoL improvement, but a single unreplicated composite-score signal in one subgroup isn't enough to justify dedicating a paragraph of the article body, and a meta dimension without article coverage breaks the score/body coupling. Downgraded for honesty. The Filip trial is still flagged in the dossier.
beauty_cumulative: 0 — same reasoning. The "minor side-effect of internal-health improvement on long-term look" argument is real but generic to almost any cardiometabolic intervention; without a substance-specific aesthetic mechanism or trial, the article cannot support a beauty paragraph honestly.

Excluded by choice.

The cancer / anti-tumour literature. Real in-vitro and animal evidence on oleuropein and tumour-cell apoptosis exists, but no human trial; the MSK monograph is explicit that OLE has not been shown to prevent or treat cancer in humans. Including it would have inflated the case and confused the reader.
Detailed pharmacokinetics of oleuropein bioavailability. Important for product comparison but beyond the catalogue's reader.
Generic "antioxidant" framing. Too vague to anchor any reader decision.

Future-link candidates. Once they exist: an entry on home blood-pressure monitoring (the responder-detection tool this substance needs), an entry on extra-virgin olive oil / Mediterranean dietary pattern, and an entry on when borderline hypertension warrants medication. The out-of-scope section signposts these for the reader.

Dream narrative. Computed overall score landed around 20, well below the 40 threshold. The honest hook is "modest, real adjunct for a specific reader" — an aspiration projection ("the version of you that…") would ring false at this magnitude. Dek and tagline written straight, per article.md §2 / headline.md §2. A relief-lever framing was considered (cheap, real, against an industry full of puffery) but the dek already carries that voice without dressing it up.

Contraindication choices. Used pregnancy, breastfeeding, diabetes-medication, blood-thinners. Considered adding uncontrolled-hypertension but rejected: that is a "see a doctor" framing, not a "don't take this" framing, and the article's failure-modes section carries the message better than a token.